Drug profile

The FDA adverse-event record for Tick Prevention

12 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Tick Prevention. See the species affected, top reactions, and outcomes below.

12
adverse-event reports
25.0%
death-coded share
Dog
most-reported species
3
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
3
Deaths Reported
25.0%
Death Rate

Active Ingredients

Tick Prevention

Administration Routes

UnknownTopical

Species Affected

Dog 10
Cat 1
Horse 1

Most Affected Breeds

Retriever - Golden 1
Terrier - Yorkshire 1
Crossbred Canine/dog 1
Domestic Shorthair 1
Siberian Husky 1
Dachshund (unspecified) 1
Paint 1
Dog (unknown) 1
Pekingese 1
Collie (unspecified) 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 3
Death by euthanasia 2
Decreased appetite 2
Lack of efficacy (ectoparasite) - flea 2
Lack of efficacy - NOS 2
Bloody diarrhoea 2
Anaemia NOS 1
Hypersalivation 1
Tachypnoea 1
Systemic disorder NOS 1
Laboured breathing 1
Pleural effusion 1

Outcome Breakdown

Ongoing
5 (41.7%)
Outcome Unknown
3 (25.0%)
Euthanized
2 (16.7%)
Recovered/Normal
1 (8.3%)
Died
1 (8.3%)

Tick Prevention Adverse Event Insights

12 reports name Tick Prevention; 3 recorded a death outcome (25.0% of reported events, not a population-level mortality rate). Active ingredient: Tick Prevention. Administration routes: Unknown, Topical.

By species: Dog (10 reports), Cat (1 reports), Horse (1 reports). By breed: Retriever - Golden (1), Terrier - Yorkshire (1), Crossbred Canine/dog (1).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (3), Death by euthanasia (2), Decreased appetite (2), Lack of efficacy (ectoparasite) - flea (2). Outcome, 12 coded reports: Ongoing leads at 41.7%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.